Marchés français ouverture 3 h 16 min
  • Dow Jones

    28 335,57
    -28,13 (-0,10 %)
     
  • Nasdaq

    11 548,28
    +42,28 (+0,37 %)
     
  • Nikkei 225

    23 484,68
    -31,91 (-0,14 %)
     
  • EUR/USD

    1,1840
    -0,0028 (-0,24 %)
     
  • HANG SENG

    24 918,78
    +132,68 (+0,54 %)
     
  • BTC-EUR

    11 086,99
    +33,97 (+0,31 %)
     
  • CMC Crypto 200

    263,89
    +2,43 (+0,93 %)
     
  • S&P 500

    3 465,39
    +11,90 (+0,34 %)
     

Idiopathic Pulmonary Fibrosis - Epidemiology Forecast to 2029

ReportLinker
·3 min de lecture

Summary Idiopathic pulmonary fibrosis (IPF) is a type of interstitial lung disease and is a serious chronic condition that affects the tissue surrounding the air sacs, or alveoli, in the lungs.

New York, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Idiopathic Pulmonary Fibrosis - Epidemiology Forecast to 2029" - https://www.reportlinker.com/p05975182/?utm_source=GNW
This condition occurs when the lung tissue becomes thick and stiff for unknown reasons.

Over time, breathing becomes difficult due to fibrosis caused by permanent scarring in the lungs (NHLBI, 2019). IPF is associated with a poor prognosis, with a median survival of three to five years (Raghu et al., 2011). There is currently no cure for IPF. However, certain medicines may slow the progression of IPF, which may extend the lifespan and improve the quality of life for people who have the disease (NHLBI, 2019).

Epidemiologists utilized county-specific studies published in peer-reviewed journals to build the forecast.epidemiologists used sources that confirmed IPF cases through both a biopsy of the lung and high-resolution computed tomography (HRCT).

The report includes a 10-year epidemiological forecast for the diagnosed incident and prevalent (total and diagnosed) cases of IPF in the 7MM, segmented by age, sex, severity, and comorbidities.

The following data describes epidemiology of IPF. In the 7MM, epidemiologists forecast an increase in the diagnosed incident cases of IPF from 28,301 cases in 2019 to 32,997 cases in 2019, at an AGR of 1.66% over the forecast period. The diagnosed prevalent cases of IPF in the 7MM will increase from 130,822 cases in 2019 to 153,747 cases in 2029, at an AGR of 1.75% over the forecast period. The total prevalent cases of IPF in the 7MM will increase from 201,698 cases in 2019 to 237,113 cases in 2029, at an AGR of 1.76% over the forecast period. IPF is more common in men, and the incidence and prevalence of IPF typically increases with advancing age. These trends are reflected in forecast for the diagnosed incident and prevalent (total and diagnosed) cases for the 7MM.

Scope
- The Idiopathic Pulmonary Fibrosis (IPF) Epidemiology Report provides an overview of the risk factors and global trends of IPF in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- The report includes a 10-year epidemiological forecast for the diagnosed incident and prevalent cases of IPF (total and diagnosed) segmented by sex and age (ages ?18 years). The prevalent cases of IPF (total and diagnosed) are also segmented by severity (mild, moderate, and severe), and comorbidities (pulmonary hypertension, chronic obstructive pulmonary disease, lung cancer, sleep apnea, pulmonary embolism, gastro-esophageal reflux disease, and depression). In addition, the model corresponding to this report includes age- and sex-specific mortality for IPF for ages 18 years and older.
- The IPF epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to Buy
The Idiopathic Pulmonary Fibrosis Epidemiology series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global IPF market.
- Quantify patient populations in the global IPF market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for IPF therapeutics in each of the markets covered.
- Understand magnitude of IPF population by severity at diagnosis.
Read the full report: https://www.reportlinker.com/p05975182/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001